Adiponectin – a key adipokine in the metabolic syndrome

By J. Whitehead, A. A. Richards, I. Hickman, G. Macdonald, J. Prins. Diabetes, obesity and metabolism, 2006

658 citations recorded by the source corpus.

Subfields: Endocrine and Autonomic Systems, Epidemiology, Physiology

View Paper: https://www.semanticscholar.org/paper/0e6743ef305d22f135159bc6693cf2312da2c086

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrine and Autonomic Systems

1. Sushil Kumar Jain
2. A. Achari

In Epidemiology

1. André Tchernof
2. P. Newsome
3. J. Despres
4. Philippe Froguel
5. Kassem Makki
6. Sushil Kumar Jain
7. J. Tomlinson
8. J. Dowman

In Physiology

1. J. Despres
2. Philippe Froguel
3. Kassem Makki
4. Sushil Kumar Jain
5. André Tchernof
6. I. Wolowczuk
7. A. Achari

Citations in the corpus

• Adipose Tissue in Obesity-Related Inflammation and Insulin Resistance: Cells, Cytokines, and Chemokines (2013, positive): “TNF-α also downregulates the mRNA levels of adiponectin [26], an adipocyte-derived hormone which contributes to the maintenance of peripheral glucose and lipid homeostasis [27].”
• Obesity, Metabolic Syndrome, and Cardiovascular Disease (2007, background): “Adiponectin, which acts as a regulator of MS (37), might be cardio-protective by inhibiting TNF- -mediated monocyte adhesion, formation of foam cells and smooth muscle cell proliferation and also by promoting blood vessel growth and endothelial NO production (38).”
• Pathophysiology of human visceral obesity: an update. (2013, background): “Circulating concentrations of adiponectin, an adipocytederived adipokine with insulin-sensitizing and anti-inflammatory properties, are inversely associated with visceral obesity (617).”
• Pathogenesis of non-alcoholic fatty liver disease (2009, background): “Adiponectin antagonises the effects of TNF-a, which itself suppresses adiponectin production.(61) The importance of adiponectin in NAFLD is supported by studies showing that serum adiponectin levels can help to distinguish NASH from simple steatosis.”
• Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction (2017, background): “Adipose tissue, which is primarily composed of adipocytes as well as pre-adipocytes, macrophages, endothelial cells, fibroblasts, and leucocytes, has been increasingly recognized as a major player of systemically metabolic regulation [87].”